A Clinical trial to study the effects of two drugs,Nimbadi guggulu and Pathyashadangam Ghanavati in patients with Migraine.

A RANDOMISED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF NIMBADI GUGGULU IN THE MANAGEMENT OF ARDHAVABHEDAKA (MIGRAINE)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/06/034009

Enrollment

Registered

2021-06-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Intervention1: NIMBADI GUGGULU: PATIENT HAVE TO ORALLY INTAKE 2 TABLETS OF 500 mg TWICE A DAY ALONG WITH WATER FOR 30 DAYS Control Intervention1: PATHYADI GHANAVATI: PATIENT HAVE TO ORALLY INTAKE 2 TA

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 16 â?? 60 years irrespective of gender religion and socioeconomic status will be selected Patients presenting with clinical features of Ardhavabhedaka will be selected

Exclusion criteria

Exclusion criteria: Patients having other types of Shirashula apart from Ardhavabhedaka will be excluded. Patients suffering from secondary headaches like sinusitis, meningitis etc. will be excluded. Patients with any other systemic diseases and pregnancy will be excluded.

Design outcomes

Primary

Measure	Time frame
Bheda Todavat Shula( Intensity of pain) Duration of single episode Frequency of attack Photophobia Nausea Vomiting Timepoint: 90 DAYS	—

Secondary

Measure	Time frame
NOT APLICABLETimepoint: NOT APLICABLE	—

Countries

India

Contacts

Public ContactDr Apeksha D Rao

ALVAS AYURVEDA MEDICAL COLLEGE AND HOSPITAL

drapekshadrao@gmail.com7411360991

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026